March 23rd 2025, PDC*line Pharma is presenting new results from its ongoing clinical development program at the European Lung Cancer Congress 2025, during the poster session — in the presence of our...
We’re proud to share our latest research, conducted in collaboration with the Etablissement Français du Sang (EFS), now published in Hepatology Communications! This study showcases the potential of PD...
PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024
PDC*lung01, in combination with pembrolizumab, demonstrates the potential to provide...
We are thrilled to announce that BioProcess International, a leading global platform for the bioprocessing industry, has published a new article featuring an interview with our CEO, Eric Halioua. In...
PDC*line Pharma is thrilled to announce that the primary clinical analysis results from our Phase I/II trial (PDC-LUNG-101) will be presented as a mini oral presentation at the European Society for...
We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI), held in Strasbourg...
We are delighted to announce that we have been selected for an oral presentation at the International Session of the 50th Annual Meeting of Korean Cancer Association (KCA 2024)! PDC*line Pharma...
We are delighted to announce that we have been selected for an oral presentation at the 37th European Immunogenetics and Histocompatibility (EFI) Conference!
The presentation has been made May 21th by...
We are delighted to announce that we have been selected for both a poster and short talk presentation at the CIMT 2024 annual meeting!
The short talk has been made by Sebastien Michel May 16th in...
Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patients
Combinatio...
